Zum Hauptinhalt springen
OncoBeta logoOncoBeta logo

South Africa: Skin Cancer Symposium

You are invited to the industry symposium hosted by OncoBeta Africa

When: 8:00 – 9:00am on Saturday 2nd March, 2024
Where: UCT Academic Conference Centre, V&A Waterfront, Cape Town
Title: "Personalized irradiation therapy for NMSC by Rhenium-188 skin cancer therapy: South African Clinical Experience"

Speakers:

  • Prof Mokoala
  • Prof Sathekge
  • Prof Lenhloenya

OncoBeta Africa is honoured to sponsor and actively participate in the Skin Cancer Symposium, a pivotal event dedicated to advancing knowledge and innovation in the field of skin cancer treatment. As a leader in cancer therapy, we're committed to supporting initiatives that promote education, collaboration, and excellence in patient care. At this year's symposium, we're excited to showcase our revolutionary Rhenium-SCT technology, which offers a targeted* and minimally invasive** approach to treating non-melanoma skin cancer.1-4

 

Join us on Saturday, March 2nd, at 8am for the industry symposium, where experts will present and discuss their own clinical experience and best practices in skin cancer management.

Together, let's continue to raise awareness, drive progress, and improve outcomes for patients affected by this prevalent disease.

For more information about the Skin Cancer Symposium, including the scientific program and registration details, please visit their website: https://skincancersymposium.co.za/

OncoBeta Africa is proud to support this industry event as a Gold Sponsor.

Event: Melanoma Society South Africa: Skin Cancer Symposium

Where: UCT Academic Conference Centre, V&A Waterfront, Cape Town

 

*Precise/targeted: Accurate dosing. Spares healthy tissue.

**Non-invasive: A procedure is considered non-invasive when no break or cut in the skin is created.

 

References:

  1. Cipriani C, et al. J Dermatol Treat. 2022;33(2):969–975. Epub 22 Jul 2020.
  2. Cipriani C, et al. Int J Nucl Med. 2017;114–122.
  3. Castellucci P, et al. Eur J Nucl Med Mol Imaging. 2021;48(5):1511–1521.
  4. Australian Therapeutic Goods Administration. ARTG Public summary 400142.
Back
OncoBeta symposium invitation